Mirador Capital Partners LP Buys 11,662 Shares of Pfizer Inc. $PFE

Mirador Capital Partners LP boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 31.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,575 shares of the biopharmaceutical company’s stock after purchasing an additional 11,662 shares during the quarter. Mirador Capital Partners LP’s holdings in Pfizer were worth $1,177,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in PFE. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the first quarter worth about $27,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the first quarter worth about $28,000. North Capital Inc. acquired a new stake in shares of Pfizer during the first quarter worth about $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the fourth quarter worth about $30,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.4%

Shares of NYSE:PFE opened at $23.88 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a fifty day moving average of $24.73 and a two-hundred day moving average of $24.25. The stock has a market cap of $135.77 billion, a P/E ratio of 12.70, a PEG ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PFE. Morgan Stanley lifted their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Berenberg Bank reduced their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.